Irish Jian 4

What Happened Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics (MGX), disposed of 3,737 shares on June 5, 2026 at $1.30 per share for proceeds of $4,854. The filing states this sale was an automatic disposition to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) and was not a volitional trade by the reporting person.

Key Details

• Transaction date and price: June 5, 2026 — sale of 3,737 shares at $1.30 each (total ≈ $4,854).
• Reason/code: Tax withholding on vested RSUs (footnote F1) — sale not initiated as a discretionary market trade.
• Related holdings noted: filing includes 1,500 shares acquired under the company ESPP on May 29, 2026 (F2); certain shares are held in irrevocable trusts with disclaimers of beneficial ownership (F3, F4).
• Filing: Report filed on June 10, 2026 for a June 5 transaction (file appears to have been filed after the standard two-business-day Form 4 deadline).

Context Tax-withholding sales of vested RSUs are common and generally reflect routine payroll tax handling rather than a signal of insider sentiment. The filing clarifies the sale was to cover withholding for RSUs granted April 1, 2024 and April 1, 2025. The report does not specify total shares beneficially owned after the transaction.